Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin‐like protein 4 and vascular endothelial growth factor via neuropilin/ RhoA signaling

Key Result

Ginsenoside Rg3 combined with ranibizumab significantly reduces vascular permeability in diabetic macular edema through synergistic action on ANGPTL4 and VEGF.

Key Points

• The study aims to evaluate how ginsenoside Rg3 enhances the effects of ranibizumab in reducing vascular permeability related to diabetic macular edema.
• Examined the effects of ginsenoside Rg3 alongside ranibizumab.
• Analyzed the regulation of ANGPTL4 and VEGF.
• Investigated the NRP/RhoA signaling pathway.
• The combination significantly reduced vascular permeability in diabetic macular edema models.
• Synergistic action was observed in antagonizing both ANGPTL4 and VEGF.
• The findings support the potential of using combined therapies for enhanced outcomes.